97 related articles for article (PubMed ID: 8058306)
21. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.
Girard L; Zöchbauer-Müller S; Virmani AK; Gazdar AF; Minna JD
Cancer Res; 2000 Sep; 60(17):4894-906. PubMed ID: 10987304
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.
Chen JJ; Yao PL; Yuan A; Hong TM; Shun CT; Kuo ML; Lee YC; Yang PC
Clin Cancer Res; 2003 Feb; 9(2):729-37. PubMed ID: 12576442
[TBL] [Abstract][Full Text] [Related]
23. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
24. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
Lee HW; Han JH; Kim JH; Lee MH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS; Lim HY
Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
[TBL] [Abstract][Full Text] [Related]
25. Small cell lung carcinoma exhibits greater phospholipase C-beta1 expression and edelfosine resistance compared with non-small cell lung carcinoma.
Strassheim D; Shafer SH; Phelps SH; Williams CL
Cancer Res; 2000 May; 60(10):2730-6. PubMed ID: 10825148
[TBL] [Abstract][Full Text] [Related]
26. NSP-encoded reticulons are neuroendocrine markers of a novel category in human lung cancer diagnosis.
van de Velde HJ; Senden NH; Roskams TA; Broers JL; Ramaekers FC; Roebroek AJ; Van de Ven WJ
Cancer Res; 1994 Sep; 54(17):4769-76. PubMed ID: 8062278
[TBL] [Abstract][Full Text] [Related]
27. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
28. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
29. Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer.
Caputi M; Groeger AM; Esposito V; De Luca A; Masciullo V; Mancini A; Baldi F; Wolner E; Giordano A
Clin Cancer Res; 2002 Dec; 8(12):3850-6. PubMed ID: 12473599
[TBL] [Abstract][Full Text] [Related]
30. Expression of p16 and lack of pRB in primary small cell lung cancer.
Yuan J; Knorr J; Altmannsberger M; Goeckenjan G; Ahr A; Scharl A; Strebhardt K
J Pathol; 1999 Nov; 189(3):358-62. PubMed ID: 10547597
[TBL] [Abstract][Full Text] [Related]
31. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
[TBL] [Abstract][Full Text] [Related]
32. Reduced transcription of the RB2/p130 gene in human lung cancer.
Xue Jun H; Gemma A; Hosoya Y; Matsuda K; Nara M; Hosomi Y; Okano T; Kurimoto F; Seike M; Takenaka K; Yoshimura A; Toyota M; Kudoh S
Mol Carcinog; 2003 Nov; 38(3):124-9. PubMed ID: 14587097
[TBL] [Abstract][Full Text] [Related]
33. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification.
Shivapurkar N; Reddy J; Matta H; Sathyanarayana UG; Huang CX; Toyooka S; Minna JD; Chaudhary PM; Gazdar AF
Oncogene; 2002 Dec; 21(55):8510-4. PubMed ID: 12466971
[TBL] [Abstract][Full Text] [Related]
34. Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro-gastrin-releasing peptide mRNA.
Saito T; Kobayashi M; Harada R; Uemura Y; Taguchi H
Cancer; 2003 May; 97(10):2504-11. PubMed ID: 12733150
[TBL] [Abstract][Full Text] [Related]
35. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
36. RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix.
Kratzke RA; Shimizu E; Geradts J; Gerster JL; Segal S; Otterson GA; Kaye FJ
Cell Growth Differ; 1993 Aug; 4(8):629-35. PubMed ID: 8398904
[TBL] [Abstract][Full Text] [Related]
37. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
38. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis.
Naeem M; Dahiya M; Clark JI; Creech SD; Alkan S
Hum Pathol; 2002 Dec; 33(12):1182-7. PubMed ID: 12514786
[TBL] [Abstract][Full Text] [Related]
39. Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome.
Joseph MG; Banerjee D; Kocha W; Feld R; Stitt LW; Cherian MG
Cancer; 2001 Aug; 92(4):836-42. PubMed ID: 11550155
[TBL] [Abstract][Full Text] [Related]
40. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
Wu WG; Soria JC; Wang L; Kemp BL; Mao L
Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
